Recombinant protein- and synthetic peptide-based immunoblot test for diagnosis of neurocysticercosis

John Noh, Silvia Rodriguez, Yeuk Mui Lee, Sukwan Handali, Armandoe Gonzalez, Robert H Gilman, Victor C W Tsang, Hector H. Garcia, Patricia P. Wilkins

Research output: Contribution to journalArticle

Abstract

One of the most well-characterized tests for diagnosing neurocysticercosis (NCC) is the enzyme-linked immunoelectrotransfer blot (EITB) assay developed at the CDC, which uses lentil lectin-bound glycoproteins (LLGP) extracted from Taenia solium cysticerci. Although the test is very reliable, the purification process for the LLGP antigens has been difficult to transfer to other laboratories because of the need for expensive equipment and technical expertise. To develop a simpler assay, we previously purified and cloned the diagnostic glycoproteins in the LLGP fraction. In this study, we evaluated three representative recombinant or synthetic antigens from the LLGP fraction, individually and in different combinations, using an immunoblot assay (recombinant EITB). Using a panel of 249 confirmed NCC-positive and 401 negative blood serum samples, the sensitivity of the recombinant EITB assay was determined to be 99% and the specificity was 99% for diagnosing NCC. We also tested a panel of 239 confirmed NCC-positive serum samples in Lima, Peru, and found similar results. Overall, our data show that the performance characteristics of the recombinant EITB assay are comparable to those of the LLGP-EITB assay. This new recombinant- and synthetic antigen-based assay is sustainable and can be easily transferred to other laboratories in the United States and throughout the world.

Original languageEnglish (US)
Pages (from-to)1429-1434
Number of pages6
JournalJournal of Clinical Microbiology
Volume52
Issue number5
DOIs
StatePublished - 2014

Fingerprint

Neurocysticercosis
Recombinant Proteins
Glycoproteins
Peptides
Synthetic Vaccines
Enzymes
Taenia solium
Cysticercus
Professional Competence
Peru
Enzyme Assays
Centers for Disease Control and Prevention (U.S.)
Serum
lentil lectin
Antigens
Equipment and Supplies

ASJC Scopus subject areas

  • Microbiology (medical)
  • Medicine(all)

Cite this

Recombinant protein- and synthetic peptide-based immunoblot test for diagnosis of neurocysticercosis. / Noh, John; Rodriguez, Silvia; Lee, Yeuk Mui; Handali, Sukwan; Gonzalez, Armandoe; Gilman, Robert H; Tsang, Victor C W; Garcia, Hector H.; Wilkins, Patricia P.

In: Journal of Clinical Microbiology, Vol. 52, No. 5, 2014, p. 1429-1434.

Research output: Contribution to journalArticle

Noh, John ; Rodriguez, Silvia ; Lee, Yeuk Mui ; Handali, Sukwan ; Gonzalez, Armandoe ; Gilman, Robert H ; Tsang, Victor C W ; Garcia, Hector H. ; Wilkins, Patricia P. / Recombinant protein- and synthetic peptide-based immunoblot test for diagnosis of neurocysticercosis. In: Journal of Clinical Microbiology. 2014 ; Vol. 52, No. 5. pp. 1429-1434.
@article{83b1cfade6f349079b94b54652e2d4be,
title = "Recombinant protein- and synthetic peptide-based immunoblot test for diagnosis of neurocysticercosis",
abstract = "One of the most well-characterized tests for diagnosing neurocysticercosis (NCC) is the enzyme-linked immunoelectrotransfer blot (EITB) assay developed at the CDC, which uses lentil lectin-bound glycoproteins (LLGP) extracted from Taenia solium cysticerci. Although the test is very reliable, the purification process for the LLGP antigens has been difficult to transfer to other laboratories because of the need for expensive equipment and technical expertise. To develop a simpler assay, we previously purified and cloned the diagnostic glycoproteins in the LLGP fraction. In this study, we evaluated three representative recombinant or synthetic antigens from the LLGP fraction, individually and in different combinations, using an immunoblot assay (recombinant EITB). Using a panel of 249 confirmed NCC-positive and 401 negative blood serum samples, the sensitivity of the recombinant EITB assay was determined to be 99{\%} and the specificity was 99{\%} for diagnosing NCC. We also tested a panel of 239 confirmed NCC-positive serum samples in Lima, Peru, and found similar results. Overall, our data show that the performance characteristics of the recombinant EITB assay are comparable to those of the LLGP-EITB assay. This new recombinant- and synthetic antigen-based assay is sustainable and can be easily transferred to other laboratories in the United States and throughout the world.",
author = "John Noh and Silvia Rodriguez and Lee, {Yeuk Mui} and Sukwan Handali and Armandoe Gonzalez and Gilman, {Robert H} and Tsang, {Victor C W} and Garcia, {Hector H.} and Wilkins, {Patricia P.}",
year = "2014",
doi = "10.1128/JCM.03260-13",
language = "English (US)",
volume = "52",
pages = "1429--1434",
journal = "Journal of Clinical Microbiology",
issn = "0095-1137",
publisher = "American Society for Microbiology",
number = "5",

}

TY - JOUR

T1 - Recombinant protein- and synthetic peptide-based immunoblot test for diagnosis of neurocysticercosis

AU - Noh, John

AU - Rodriguez, Silvia

AU - Lee, Yeuk Mui

AU - Handali, Sukwan

AU - Gonzalez, Armandoe

AU - Gilman, Robert H

AU - Tsang, Victor C W

AU - Garcia, Hector H.

AU - Wilkins, Patricia P.

PY - 2014

Y1 - 2014

N2 - One of the most well-characterized tests for diagnosing neurocysticercosis (NCC) is the enzyme-linked immunoelectrotransfer blot (EITB) assay developed at the CDC, which uses lentil lectin-bound glycoproteins (LLGP) extracted from Taenia solium cysticerci. Although the test is very reliable, the purification process for the LLGP antigens has been difficult to transfer to other laboratories because of the need for expensive equipment and technical expertise. To develop a simpler assay, we previously purified and cloned the diagnostic glycoproteins in the LLGP fraction. In this study, we evaluated three representative recombinant or synthetic antigens from the LLGP fraction, individually and in different combinations, using an immunoblot assay (recombinant EITB). Using a panel of 249 confirmed NCC-positive and 401 negative blood serum samples, the sensitivity of the recombinant EITB assay was determined to be 99% and the specificity was 99% for diagnosing NCC. We also tested a panel of 239 confirmed NCC-positive serum samples in Lima, Peru, and found similar results. Overall, our data show that the performance characteristics of the recombinant EITB assay are comparable to those of the LLGP-EITB assay. This new recombinant- and synthetic antigen-based assay is sustainable and can be easily transferred to other laboratories in the United States and throughout the world.

AB - One of the most well-characterized tests for diagnosing neurocysticercosis (NCC) is the enzyme-linked immunoelectrotransfer blot (EITB) assay developed at the CDC, which uses lentil lectin-bound glycoproteins (LLGP) extracted from Taenia solium cysticerci. Although the test is very reliable, the purification process for the LLGP antigens has been difficult to transfer to other laboratories because of the need for expensive equipment and technical expertise. To develop a simpler assay, we previously purified and cloned the diagnostic glycoproteins in the LLGP fraction. In this study, we evaluated three representative recombinant or synthetic antigens from the LLGP fraction, individually and in different combinations, using an immunoblot assay (recombinant EITB). Using a panel of 249 confirmed NCC-positive and 401 negative blood serum samples, the sensitivity of the recombinant EITB assay was determined to be 99% and the specificity was 99% for diagnosing NCC. We also tested a panel of 239 confirmed NCC-positive serum samples in Lima, Peru, and found similar results. Overall, our data show that the performance characteristics of the recombinant EITB assay are comparable to those of the LLGP-EITB assay. This new recombinant- and synthetic antigen-based assay is sustainable and can be easily transferred to other laboratories in the United States and throughout the world.

UR - http://www.scopus.com/inward/record.url?scp=84899517524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899517524&partnerID=8YFLogxK

U2 - 10.1128/JCM.03260-13

DO - 10.1128/JCM.03260-13

M3 - Article

C2 - 24554747

AN - SCOPUS:84899517524

VL - 52

SP - 1429

EP - 1434

JO - Journal of Clinical Microbiology

JF - Journal of Clinical Microbiology

SN - 0095-1137

IS - 5

ER -